More Than A Screen: Hollyland Unveils The 5.5-inch All-in-One Wireless Monitor Pyro 5 to Boost Efficiency in Professional Film Production

SHENZHEN, China, Aug. 21, 2025 /PRNewswire/ — Hollyland proudly announces the launch of the Pyro 5, the latest groundbreaking addition to its Pyro Series lineup. This multifunctional device combines high-definition display, camera control, content management, and real-time transmission capabilities, making it the perfect solution for multi-user monitoring in dynamic shooting scenarios, such as film production, live events, ENG/EFP applications, and more.

Powerful, User-Friendly Features that Set Industry Standards

The Pyro 5 stands out with its powerful features and user-friendly design, setting a new industry standard. With advanced recording capabilities, including proxy recording and content tagging, post-production processes become significantly more efficient. The built-in image analysis tools, including waveform, focus assist, 3D LUTs, and zebra pattern, allow users to quickly assess image quality, enhancing overall production workflow. The Pyro 5 also features a “Ready Out of the Box” plug-and-play design that simplifies the setup process. Various power options and a quick-release antenna design ensure reliable operation in diverse environments, making transitions on set smoother and more efficient.

More than a Screen: Innovative Technology Upgrades

In addition to its robust operational capabilities, the Pyro 5 is equipped with a 5.5-inch, 1500-nit high-brightness screen, ensuring that users can easily adjust essential parameters even in challenging outdoor lighting conditions. Supporting 2.4G and 5G dual-band operation, Pyro 5 enhances signal stability and response speed, making it an ideal companion for any production setup. With HDMI and SDI loop-out options, this monitor integrates seamlessly into a variety of production environments as well.

Advantages of the Pyro Ecosystem: Enhancing Collaborative Production

Building on the strengths of the Pyro series, the Pyro 5 offers a range of ecosystem advantages that facilitate collaborative production. One of the standout features of the Pyro ecosystem is its ability to transmit one signal to four receivers using WiFi broadcast technology, enabling all crew members to monitor in real-time with stable signals. Hollyland’s proprietary Auto Frequency Hopping technology constantly scans and adjusts to find the optimal wireless channel, ensuring reliable connections over distances of up to 400 meters. This capability, combined with low latency and automatic channel optimization, guarantees real-time monitoring without delays. Additionally, the Pyro 5 supports Multi-Cam Switching, allowing seamless transitions between camera groups—an essential capability for keeping up with fast-paced live productions. When multiple Pyro systems are in use, the Lock Pairing feature ensures that each receiver remains securely connected to its original transmitter, preventing any signal mix-ups.

The Pyro 5 is now available for purchase through local distributors and Hollyland Amazon store.

For more about the pricing and detailed product information, please visit here.

Looking ahead, Hollyland plans to continue expanding its product line to develop integrated solutions that meet the growing demands of the market, driving rapid and sustainable industry growth.

ABOUT HOLLYLAND TECHNOLOGY

Shenzhen Hollyland Technology Co., Ltd. (‘Hollyland’ or ‘Hollyland Technology’) empowers global customers with professional solutions that are expressly designed for wireless data, audio, and video transmission and wireless intercom solutions since 2013. Key products include Solidcom C1, Mars 400s Pro, Mars 4K, Mars M1, Cosmo C1, and Lark M1.

Hollyland serves many markets, including filmmaking, television shooting, video production, broadcast, live streaming, live events, exhibitions, broadcast media, production, general events, theatres, houses of worship, rental houses, and more.

For more information, visit https://www.hollyland.com/, Hollyland Instagram, Hollyland Facebook, and Hollyland YouTube.

NEW YORK, Aug. 21, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Ashley Mastronardi delivers the pre-market update on August 21st

• Stocks are lower this morning as the S&P 500 looks to end a four-day losing streak amid recent pressure on the tech sector.
• The Federal Reserve remains in focus for Wall Street as the Central Bank released the latest minutes from July’s meeting on Wednesday. This shed more light on policymaker’s concerns about inflation
• NYSE-listed Disney’s sports media giant ESPN will ring the opening bell to celebrate the launch of its new streaming service.

Opening Bell
ESPN celebrates the launch of the network’s direct-to-consumer service & enhanced app

Closing Bell
Cummins (NYSE: CMI) celebrates executive leadership development

Click here to download the NYSE TV App

Video – https://mma.prnasia.com/media2/2755418/NYSE_Market_Update_August_21.mp4 

Submissions Now Open for the 2025 Data Visionary Awards Recognizing Excellence in AI and Data Innovation

BOSTON, Aug. 21, 2025 /PRNewswire/ — Starburst, the data platform for apps and AI, today announced details for AI & Datanova 2025, taking place October 9, 2025, at The Westin New York Times Square. This in-person event will bring together senior data and technology leaders, including CDOs, CIOs, CTOs, chief architects, and Starburst power users to share strategies, innovations, and best practices for turning enterprise data into real-world AI outcomes.

The program will feature a range of keynotes, customer stories, and technical sessions. A highlight will be two keynote addresses by Starburst CEO and Co-founder Justin Borgman, who will draw on his deep experience helping enterprises unlock the value of their data to outline:

• The emerging era of Enterprise Agents — autonomous, AI-powered systems capable of carrying out complex business tasks across an organization.
• The data readiness challenge — why high-quality, governed, and accessible data will be the deciding factor in AI success over the next three to five years.
• The blueprint for enabling AI at enterprise scale — including the role of federated query, governance, and real-time access in powering next-generation applications.
• Predictions for the AI-driven enterprise — from the transformation of decision-making to entirely new categories of customer experiences.

Borgman’s keynote will expand on these themes, offering concrete strategies and real-world customer examples of how leading organizations are building their data foundations to take full advantage of the AI revolution. Additional featured speakers include executives and senior leaders from Arity, Expedia, OCBC Bank, and more.

“AI & Datanova 2025 is designed to give data and technology leaders the strategies, insights, and peer connections they need to drive tangible AI outcomes,” said Lisa Luscap, Chief Marketing Officer, Starburst. “Justin’s keynote will set a powerful vision for the AI-enabled enterprise, while the event overall will provide practical, actionable guidance that attendees can bring back to their organizations. It’s a one-of-a-kind opportunity to see where the future of data and AI is headed.”

Registration details are available at https://www.starburst.io/ai-and-datanova/#register

Submissions Now Open for the 2025 Data Visionary Awards

In conjunction with the event, Starburst also announced that submissions are now open for the 2025 Data Visionary Awards. These awards honor customers and partners who are using data and AI to deliver transformative results and redefine what’s possible in their industries.

Award categories include:

• AI & Data Visionary Award
• Executive AI & Data Visionary Award
• Data AI Award
• Impact Through AI Award
• Data Pathfinder Award
• Data Disruptor Award

In addition, partner-specific awards will recognize outstanding contributions by region, as well as the Implementation Partner of the Year.

Key details:

• Submission deadline: September 5, 2025
• Winners announced: October 9, 2025, live at AI & Datanova 2025 in New York
• Eligibility: Customers, employees, and partners may submit nominations, including multiple categories if desired

Full award details and nomination forms are available at https://www.starburst.io/ai-and-datanova/data-visionary-awards/.

About Starburst
Starburst is the data platform built for flexibility, delivering fast, secure access to all your data, wherever it lives. Whether on-premises, across clouds, or in hybrid environments, Starburst provides choice and control to your architecture. Built on an open data stack with Trino and Apache Iceberg, it unifies distributed data without complex or costly migrations, unleashing the full power of the data lakehouse for analytics and AI.

With our Lakeside AI architecture, enterprises gain federated access, governed collaboration, and full data lineage, laying the foundation for scalable, compliant AI innovation. Starburst empowers data-intensive and security-conscious organizations to unlock the full potential of their data while ensuring performance, governance, and control.

Enterprises in 60+ countries, including Comcast, Citigroup, and 4 of the top 5 global banks, trust Starburst to maximize data value. Our strategic partnerships with AWS, Dell Technologies, and top cloud providers ensures seamless interoperability across environments.

From insights to action to AI, Starburst fuels innovation at every level. Learn more at starburst.ai.

Fully integrated AI decision support tool flags B scans that may require further review, supporting more confident decision making and more efficient patient care.

JENA, Germany, Aug. 21, 2025 /PRNewswire/ — ZEISS Medical Technology today announced CE mark approval for CIRRUS^® PathFinder™, an innovative clinical support tool with artificial intelligence (AI) fully integrated to enable more confident decision-making and accelerate a clinician’s workflow with OCT interpretation assistance. ZEISS CIRRUS PathFinder¹ uses proprietary deep learning algorithms to automatically identify abnormal macular OCT B-scans as a licensed element of a new CIRRUS software release, that also provides AI-enhanced OCTA image quality and multi-layer segmentation, helping to improve a practice’s workflow efficiency and patient care.

“At ZEISS, we continue to develop digital diagnostic tools that help streamline workflows, lower costs, improve outcomes, and elevate the patient experience,” says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. “The AI decision support capabilities of ZEISS CIRRUS PathFinder help enable faster, more informed and actionable diagnostics for a better clinical and patient experience.”

“ZEISS is harnessing the power of data and artificial intelligence to deliver integrated digital solutions that are paving the way for the next era in ophthalmic care,” says Euan S. Thomson, Ph.D., Head of the Digital Business Unit for ZEISS Medical Technology. “Our strategic focus on digitally connected workflows has placed us at the forefront for enabling ophthalmologists with powerful AI-driven capabilities, like those that have been fully integrated into ZEISS CIRRUS PathFinder.”

New research shows that physicians who leverage AI algorithms can be more effective than a practitioner alone. ZEISS CIRRUS with PathFinder delivers high-speed image capture with HD imaging detail ², a wide field of view, and AI decision support, helping clinicians make more informed and efficient decisions.

“With PathFinder AI Decision Support, our game-changing technology identifies OCT B-scans that may require additional review, raising our advanced diagnostic portfolio to a new level of patient care support,” says Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology.   

Improved clinical decision support – Without requiring export and data analysis from third-party platforms, CIRRUS PathFinder’s fully integrated AI decision support algorithm interprets data within the clinician’s current workflow, allowing for the assessment of many hundreds of scans at once, in real time, upleveling the value of a clinician’s time. During image acquisition, this AI-guided workflow tool flags areas that may require more detailed imaging and, during review, allows the user to focus on what matters – improving patient care.

Improved OCTA image quality – New CIRRUS operating software provides AI-enhanced visualization of the vascular structure and B-scan averaging of the OCTA structural scans. Increased layer segmentation further enhances the user’s diagnostic capability for even more efficient decision making.

Enhanced connectivity and security – New cybersecurity features are designed to meet ever-evolving compliance and security needs. Additionally, the ZEISS CIRRUS platform ensures the seamless review of legacy OCT data combined with other diagnostic modalities to further enhance patient care.

CIRRUS^® PathFinder™ is available via license within the new CIRRUS software update, which includes an expanded Reference Database (RDB) that is triple the size of the previous RDB, cybersecurity enhancements, multi-layer segmentation, and improved OCTA visualization. The software update is available in select markets.

For more information about CIRRUS PathFinder, go here.

¹ ZEISS PathFinder works on all current ZEISS CIRRUS devices: 500, 5000, 6000, however RDB2 is for ZEISS CIRRUS 6000 data only.
² As it relates to the ZEISS CIRRUS 6000 only.

Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals’ content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. 

Contact for investors
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220 116
Mail: investors.meditec@zeiss.com

Contact for the press
Frank Smith
Head of Global Communications
ZEISS Ophthalmology
Carl Zeiss Meditec Inc.
Phone: +49 3641 220 331
Mail: press.med@zeiss.com

www.zeiss.com/newsroom          

Brief Profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.com/med

• Received the highest grade for the entire R&D process, from design to quality verification
• Plans to mass-produce 20 million units of 16 major semiconductors developed in-house this year, and has established an R&D environment at the global top level
• Takes the lead in expanding the domestic automotive semiconductor partnership ecosystem

SEOUL, South Korea , Aug. 21, 2025 /PRNewswire/ — Hyundai Mobis has obtained the highest grade of ISO 26262 certification, an international standard for functional safety, for its entire vehicle semiconductor R&D process. It is noted that this rigorous certification was obtained not for specific products, but for the entire process ranging from semiconductor design to quality verification.

This certification means that when Hyundai Mobis designs semiconductors through the standardized R&D process in the future, the semiconductors designed through the process will have the same level of reliability as those certified as products. Hyundai Mobis plans to actively share these achievements and know-how with its major partners and take the lead in expanding the domestic automotive semiconductor ecosystem.

Hyundai Mobis announced on the 21st that it has obtained ISO 26262: 2018 2nd edition from Exida, a world-renowned automotive functional safety and cybersecurity certification agency based in Germany. ISO 26262 is an international standard for preventing safety accidents in automotive electrical and electronic systems.

Along with ISO 26262 certification, Hyundai Mobis received the highest D grade in the Automotive Safety Integrity Level (ASIL). ASIL is divided into four levels from A to D, with D requiring a strict reliability of 99% or higher to prevent safety accidents.

With this certification, Hyundai Mobis has proven its semiconductor design capabilities and technological stability through an authoritative external institution. These achievements can be attributed to Hyundai Mobis’ acquisition of Hyundai Autron in 2021, which enabled the company to begin mass production of its own semiconductors this year, backed by its industry-leading R&D environment.

• A total of 16 types of semiconductors are scheduled to be mass-produced at 20 million units this year…expected to lead to the company‘s improved competitiveness in core components

Hyundai Mobis expects this certification to enhance the competitiveness of its self-designed semiconductors and controllers and other components equipped with them. As the importance of semiconductors grows, customers are increasingly preferring suppliers with standard certifications. This certification will also positively impact Hyundai Mobis’ competitiveness in global automotive component supply contracts.

“With this certification, we have secured a strategic foundation in the automotive semiconductor sector, which will determine future mobility competitiveness. We will take the lead in establishing an R&D environment that emphasizes functional safety by strengthening partnerships with major domestic and international companies while internalizing technology,” said Lee Hee Hyun, Vice President of Hyundai Mobis’ System Semiconductor R&D Group.

Currently, Hyundai Mobis is mass-producing a total of 16 types of semiconductors, including ASIL-D-rated integrated semiconductors for airbags, power semiconductors for eco-friendly vehicles, integrated semiconductors for motor control, and power semiconductors for AVN (audio, video, and navigation) electronic components, through external foundries. The number of semiconductors to be mass-produced this year alone will exceed 20 million.

Hyundai Mobis is also accelerating research and development with the goal of completing 11 next-generation semiconductors, including semiconductors for battery management systems, lamps, and communication, and a system on a chip (SoC) for networks, within three years. To this end, the company is also collaborating with major domestic foundry companies.

• Jointly enhancing the technological competitiveness of ‘K-automotive semiconductors‘…expanding the ecosystem through sharing know-how with partner companies

Hyundai Mobis plans to actively communicate and share the know-how it has acquired through functional safety certification with major domestic and overseas partners. At the same time, it will also work to expand its own domestic automotive semiconductor ecosystem in Korea.

In fact, Hyundai Mobis is increasing its collaboration with major domestic semiconductor companies. The company established a joint lab with Global Technologies, a semiconductor design specialist, this year and achieved research and development results in semiconductors for next-generation smart ambient lighting. It has also completed the development of an integrated drive semiconductor with Dongwoon Anatech and is now moving into its mass production.

Hyundai Mobis is also strengthening partnerships with leading domestic foundry companies to expand the scope of collaboration, including process optimization. Additionally, it plans to enhance cooperation with design houses that serve as intermediaries between fabless and foundry companies, semiconductor packaging companies, and specialized firms in design, analysis, and verification, as well as research institutions.

About Hyundai Mobis

Hyundai Mobis is the global no. 6 automotive supplier, headquartered in Seoul, Korea. Hyundai Mobis has outstanding expertise in sensors, sensor fusion in ECUs and software development for safety control. The company’s products also include various components for electrification, brakes, chassis and suspension, steering, airbags, lighting, and automotive electronics. Hyundai Mobis operates its R&D headquarters in Korea, with four technology centers in the United States, Germany, China, and India. For more information, please visit the website at http://www.mobis.com

Media Contact 
Choon Kee Hwang : ckhwang@mobis.com
Jihyun Han : jihyun.han@mobis.com

• Company holds a dedicated meeting with Gates Foundation executives during Bill Gates’ visit to Korea.
• Both reviews expanded cooperation, including next-generation preventive medicines.

SEONGNAM, South Korea, Aug. 21, 2025 /PRNewswire/ — SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that the company held an exclusive meeting with the Gates Foundation in line with the visit of Bill Gates, Founder and Chair of the Foundation, to Korea to discuss ways to advance global health collaboration.

The meeting was held on August 20 in Yeouido, Seoul, and attended by Trevor Mundel, President of Global Health of the Gates Foundation, along with other key foundation representatives, as well as Andrew Chey, Vice-Chairman of SK discovery, and Jaeyong Ahn, CEO of SK bioscience.

During the meeting, both organizations reaffirmed their long-standing partnership and commitment to working together on vaccine development and global public health projects. They also explored expanded cooperation in next-generation preventive medicines, with an emphasis on R&D for pandemic preparedness.

Since 2013, SK bioscience and the Gates Foundation have collaborated on multiple initiatives, including the development of typhoid and pediatric diarrhea vaccines and other antiviral preventive solutions, contributing to global public health. A notable milestone in their collaboration was the successful development and commercialization of SKYCovione in 2022, Korea’s first domestically developed COVID-19 vaccine. That year, Bill Gates and Trevor Mundel visited Korea to celebrate the achievement, meeting with Tony Chey, Chairman of SK Group, and Andrew Chey, Vice-Chairman of SK discovery.

SK bioscience remains committed to working with global partners to advance public health and expand equitable access to vaccines worldwide.

About SK bioscience

SK bioscience is an innovative vaccine and biotech company, committed to vaccine development and manufacturing to enable more equitable access to vaccines around the world. Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. With the cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors, and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions.

– SK bioscience Website
– SK bioscience Linkedin

Contact
SK bioscience Communications Team
Changhyun Jin (jin99@sk.com)
Jeannie S. Pak (j.pak@sk.com)